Publications
40
Citations
334
Est. group size
~10
Recurring co-author estimate
Active years
11
Publishing since 2016
Typically publishes in teams of ~6 · 30% small-team papers (≤3 authors) · across 16 venues
- Abstract 3156: Pharmacokinetics of a series of anticancer agents in immunodeficient female NOD scid gamma mice
Cancer Research · 2026
- Abstract 4265: The role of the mevalonate pathway in post-translational modifications of PD-L1
Cancer Research · 2025
- Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Investigational New Drugs · 2024
- The Role of the Mevalonate pathway in Post-translational Modifications of PD-L1
Journal of Pharmacology and Experimental Therapeutics · 2024
- Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.
Journal of Clinical Oncology · 2024
- Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer
Journal of Chromatography B · 2023
- Actin Up: An Overview of the Rac GEF Dock1/Dock180 and Its Role in Cytoskeleton Rearrangement
Cells · 2022
- Therapeutic Potential of 5′-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma
Viruses · 2022
- Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism
Drug Metabolism and Disposition · 2022
- Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors
The Journal of Clinical Pharmacology · 2022
- Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128
Cancer Chemotherapy and Pharmacology · 2022
- Drug Excretion
Elsevier eBooks · 2021
- Drug Excretion
Elsevier eBooks · 2020
- Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors
Cancer Research · 2020
- The Dopamine D<sub>2</sub> Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells
Pharmacology · 2019
- Elsevier eBooks×5
- Cancer Research×3
- Diabetes×2
- Annals of Neurology×1
- Neurotherapeutics×1
- Alex Buga
Medicine · The Ohio State University
- Saroj Chakraborty
Medicine · University of Michigan
- Madison L. Kackley
Medicine · The Ohio State University
- Bret Rust
Medicine · Indiana University
- Simon S. Evers
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile